Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

BioXcellence

- PMLiVE

Boehringer takes third-generation NSCLC drug into pivotal trials

Startsphase II study of BI 1482694 in patients who test positive for T790M mutation

- PMLiVE

Boehringer’s Praxbind granted accelerated approved by FDA

Reversal agent for anticoagulant Pradaxa given the nod

Boehringer Ingelheim headquarters

Boehringer and Philogen collaborate on acute myeloid leukaemia

Hope to bring new therapies for the rare disease

Boehringer Ingelheim headquarters

Boehringer says anti-IL-23 drug beats Stelara in psoriasis trial

Interleukin-23 inhibitor outperforms Johnson & Johnson's blockbuster

- PMLiVE

MSF: TPP agreement could swell healthcare costs

But proponents say it will boost economic development

- PMLiVE

Boehringer hails its ‘landmark year’ in respiratory

Marketing and sales head Allan Hillgrove on the company's recent efforts

Tackling biosimilars – how to handle the threat to Pharma brands

Strategy Consultant Mark Assenti outlines three key points for developing a strategy to tackle the threat to Pharma brands from biosimilars.

Blue Latitude Health

- PMLiVE

Jardiance survival data wows diabetes conference

BoehringerIngelheim and Eli Lilly release top-line findings from landmark trial at EASD

- PMLiVE

Boehringer Ingelheim appoints Andreas Neumann as HR lead

He will also join the company's board ofmanaging directors

Biosimilars – the same, but different?

As more products reach European markets, US regulations are catching up with science

- PMLiVE

FDA follows WHO lead on biosimilar naming

Proposes adding suffixes to distinguish biosimilar drug names

- PMLiVE

Boehringer Ingelheim’s John Pugh set for move to Accenture

Will take up London-based role in theconsultants' digital department

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links